期刊文献+

IL-6调节Twist的表达对肝癌细胞BEL-7402上皮-间质转化的影响 被引量:2

Influence of interleukin-6 on epithelial-mesenchymal transition through the regulation of Twist expression in human hepatoma cell line BEL-7402
下载PDF
导出
摘要 目的探讨白细胞介素6(interleukin-6,IL-6)通过调节Twist的表达调控肝癌细胞上皮-间质转化(epithelial-mesenchy-mal transition,EMT)及侵袭转移的相关机制。方法用IL-6处理肝癌细胞BEL-7402,采用Transwell实验检测细胞迁移侵袭能力。采用Western blot和qRT-PCR技术检测低表达Twist对E-cadherin和vimentin蛋白表达水平的影响和mRNA表达的变化。结果 IL-6处理BEL-7402细胞后侵袭和迁移能力明显提高。相较于空白对照组(CON组)和RNA干扰阴性对照组(RNAi-NC组),在转染组RNAi-Twist细胞中,E-cadherin蛋白和mRNA的表达水平明显增加;vimentin的蛋白表达水平明显下调,而mRNA的表达水平差异无显著性。加入50 ng/ml IL-6孵育细胞24 h后,CON组和RNAi-NC组E-cadherin蛋白和mRNA表达均较未处理时明显减少,RNAi-Twist组减少的趋势不明显;vimentin蛋白表达均较未处理时明显升高,而RNAi-Twist组升高不明显,相应mRNA的表达水平差异均无显著性。结论 IL-6可提高肝癌细胞BEL-7402体外侵袭、迁移能力,促进EMT过程,其机制可能通过调节Twist的表达,从而诱导发生EMT和侵袭转移。 Purpose To investigate of the mechanism of interleukin-6 (IL-6) on epithelial-mesenchymal transition through the regula- tion of Twist expression in human hepatoma cell line BEL-7402. Methods Pretreatment with IL-6, cell migration and invasion were detected by transwell chamber assays. The influence of loss of Twist expression on the expression of E-eadherin and vimentin mRNAs and proteins was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot. Results By pretreatment with IL-6, the ability of cell migration and invasion was significantly increased. Compared to non-transfected BEL-7402 cells (control group) and those tranfected with RNAi-NC (RNAi negative control group), the expression of E-cadherin mRNA and protein remarkably increased in BEL-7402 cells transfected with RNAi-Twist. Loss of Twist expression down-regulated vimentin protein expression, but had no significant impact on vimentin mRNA expression in BEL-7402 cells and those transfected with different siRNAs. After treated with IL-6 at a final concentration of 50 ng/ml for 24 h, the expression of E-cadherin mRNA and protein remarkably de- creased in non-transfected BEL-7402 cells and those tranfected with RNAi-NC and the decreasing trend was not significant in BEL-7402 cells transfected with RNAi-Twist. The expression of vimentin protein remarkably increased in non-transfected BEL-7402 cells and those tranfected with RNAi-NC and the increasing trend was not significant in BEL-7402 cells transfected with RNAi-Twist. The expres- sion of vimentin mRNA in BEL-7402 cells and those transfected with different siRNAs was not significantly different. Conclusion IL- 6 could promote the cell invasion, migration and epithelial-mesenchymal transition process of human hepatoma cells by regulation of Twist expression and the expression of EMT protein ( E-cadherin and vimentin).
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2013年第4期351-355,共5页 Chinese Journal of Clinical and Experimental Pathology
基金 国家自然科学基金(30901452)
关键词 肝细胞肿瘤 TWIST 上皮-间质转化 E-CADHERIN VIMENTIN hepatocellular neoplasms Twist epithelial-mesenchymal transition E-cadherin vimentin
  • 相关文献

参考文献25

  • 1Siegel R, Ward E, Brawley O, et al impact of eliminating Cancer statistics, 2011 : the and racial disparities on pre- mature cancer deaths[ J]. CA Cancer J Clin, 2011,61 (4) :212 - 36.
  • 2贾晋斌,倪淑欣.肝癌治疗新药临床研究进展[J].中国医药生物技术,2011,6(2):131-133. 被引量:9
  • 3Potenta S, Zeisberg E, Kalluri R. The role of endothelial-to-mes- enehymal transition in cancer progression[ J]. Br J Cancer, 2008, 99(9) :1375 -9.
  • 4Kalluri R. EMT: when epithelial cells decide to become mesen- ehymal-like cells [ J ]. J Clin Invest, 2009,119 ( 6 ) : 14 l 7 - 9.
  • 5Yang J, Mani S A, Donaher J L, et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis [ J ]. Cell, 2004,117(7) :927 -39.
  • 6Kang Y, Massague J. Epithelial-mesenebymal transitions : twist in development and metastasis[ J]. Cell, 2004,118 (3) :277 - 9.
  • 7Hsu C P, Chung Y C. Influence of interleukin-6 on the invasive- hess of human eoIoreetal carcinoma[ J ]. Anticancer Res, 2006,26 (6B) :4607 - 14.
  • 8Kanazawa T, Nishino H, Hasegawa M, et al. Interleukin-6 direct- ly influences protiferation and invasion potential of bead and neck cancer ceils[ J]. Eur Arcb Otorhinolaryngol, 2007,264 ( 7 ) : 815 -21.
  • 9Kalluri R, Neilson E G. Epithetial-mesenchymal transition and its implications for fibrosis [ J ]. J Clin Invest, 2003,112 ( 12 ) : 1776 - 84.
  • 10Zavadil J, Bottinger E P. TGF-beta and epithelial-to-mesenchymaltransitions[J]. Oncogene, 2005,24(37) :5764 -74.

二级参考文献27

  • 1赵超尘,李君,王平,王学浩.酪丝亮肽治疗手术不能切除的原发性肝癌临床疗效观察[J].中国现代医学杂志,2007,17(3):357-359. 被引量:8
  • 2O'Brien K, Cokkinides V, Jemal A, et al. Cancer statistics for Hispanics, 2003. CA Cancer J Clin, 2003, 53(4):208-226.
  • 3Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4):378-390.
  • 4Cheng A, Kang Y, Chen Z, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol, 2008, 26(20 Suppl):4509.
  • 5Hossain MM, Hosono-Fukao T, Tang R, et al. Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology, 2010, 20(2): 175-186.
  • 6Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs, 2008, 17(11):1769-1776.
  • 7Liu CJ, Lee PH, Lin DY, et al. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage. J Hepatol, 2009, 50(5):958-968.
  • 8A Service of the U.S. National Institutes of Health. Phase Ⅲ Study of PI-88 in Post-Resection Hepatocellular Carcinoma (PATHWAY), NCT00568308. (2008-07-22) [2011-02-25]. http://www.clinicaltrials. gov/ct2/show/NCT00568308?term=NCT00568308&rank= 1.
  • 9A Service of the U.S. National Institutes of Health. Soratemb as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma (STORM), NCT00692770. (2011-01-24) [2011-02-25]. http://www.clinicaltrials.gov/ct2/show/NCT00692770?term=NCT006 92770&rank=l.
  • 10Lu R, Jia J, Bao L, et al. Experimental study of the inhibition of human hepatocarcinoma BEL7402 ceils by the tripeptide tyroserleutide(YSL). Cancer Chemother Pharmacol, 2006, 57(2):248- 256.

共引文献12

同被引文献16

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部